Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Rheumatology
Published in: Pediatric Rheumatology 1/2010

Open Access 01-12-2010 | Research

Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study

Authors: Gunhild Lien, Thor Ueland, Kristin Godang, Anne M Selvaag, Øystein T Førre, Berit Flatø

Published in: Pediatric Rheumatology | Issue 1/2010

Login to get access

Abstract

Background

The clinical relevance of observations of serum levels of osteoprotegerin (OPG) and receptor activator of nuclear factor -κB ligand (RANKL) in juvenile idiopathic arthritis (JIA) is not clear. To elucidate the potential role of OPG and RANKL in JIA we determined serum levels of OPG and RANKL in patients with early JIA compared to healthy children, and prospectively explored changes in relation to radiographic score, bone and lean mass, severity of the disease, and treatment.

Methods

Ninety children with early oligoarticular or polyarticular JIA (ages 6-18 years; mean disease duration 19.4 months) and 90 healthy children individually matched for age, sex, race, and county of residence, were examined at baseline and 2-year follow-up. OPG and RANKL were quantified by enzyme-immunoassay. Data were analyzed with the use of t-tests, ANOVA, and multiple regression analyses.

Results

Serum OPG was significantly lower in patients than controls at baseline, and there was a trend towards higher RANKL and a lower OPG/RANKL ratio. Patients with polyarthritis had significantly higher increments in RANKL from baseline to follow-up, compared to patients with oligoarthritis. RANKL was a significant negative predictor for increments in total body lean mass. Patients who were receiving corticosteroids (CS) or disease-modifying antirheumatic drugs (DMARDs) at follow-up had higher OPG/RANKL ratio compared with patients who did not receive this medication.

Conclusions

The data supports that levels of OPG are lower in patients with JIA compared to healthy children, and higher levels of RANKL is associated with more serious disease. RANKL was a significant negative predictor of lean mass in patients with JIA. The OPG/RANKL ratio was higher in patients on DMARDs or CS treatment.
Appendix
Available only for authorised users
Literature
1.
Takayanagi H: Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007, 7: 292-304. 10.1038/nri2062.CrossRefPubMed
2.
Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER Teepe MC, DuBose RF, Cosman D, Galibert L: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997, 390: 175-179. 10.1038/36593.CrossRefPubMed
3.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliot R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 93: 165-176. 10.1016/S0092-8674(00)81569-X.CrossRefPubMed
4.
Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997, 272: 25190-25194. 10.1074/jbc.272.40.25190.CrossRefPubMed
5.
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998, 95: 3597-3602. 10.1073/pnas.95.7.3597.PubMedCentralCrossRefPubMed
6.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997, 89: 309-319. 10.1016/S0092-8674(00)80209-3.CrossRefPubMed
7.
Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004, 292: 490-495. 10.1001/jama.292.4.490.CrossRefPubMed
8.
Geusens PP, Landewe RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DM, van der Linden S, Boers M: The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 2006, 54: 1772-1777. 10.1002/art.21896.CrossRefPubMed
9.
Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM: RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford). 2006, 45: 1068-1076. 10.1093/rheumatology/kel045.CrossRef
10.
Varsani H, Patel A, van Kooyk Y, Woo P, Wedderburn LR: Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). Rheumatology (Oxford). 2003, 42: 583-590.
11.
Sarma PK, Misra R, Aggarwal A: Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol. 2008, 27: 289-294. 10.1007/s10067-007-0701-3.CrossRefPubMed
12.
Spelling P, Bonfa E, Caparbo VF, Pereira RM: Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?. Scand J Rheumatol. 2008, 1-6.
13.
Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D: Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin Endocrinol (Oxf). 2004, 60: 87-91. 10.1111/j.1365-2265.2004.01951.x.CrossRef
14.
Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, Vierucci S, Brandi ML, Falcini F: Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?. J Rheumatol. 2004, 31: 986-991.PubMed
15.
Lien G, Selvaag AM, Flato B, Haugen M, Vinje O, Sorskaar D, Dale K, Egeland T, Forre O: A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis. Arthritis Rheum. 2005, 52: 833-840. 10.1002/art.20963.CrossRefPubMed
16.
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco_Alcala J, Prieur AM, Suarez-Almazor ME, Woo P: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004, 31: 390-392.PubMed
17.
Anderssen N, Klepp KI, Aas H, Jakobsen R: Stability in physical activity levels in young adolescents. European Journal of Public Health. 1994, 4: 175-180. 10.1093/eurpub/4.3.175.CrossRef
18.
Duke PM, Litt IF, Gross RT: Adolescents' self-assessment of sexual maturation. Pediatrics. 1980, 66: 918-920.PubMed
19.
Lien G, Flato B, Haugen M, Vinje O, Sorskaar D, Dale K, Johnston V, Egeland T, Forre O: Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients. Arthritis Rheum. 2003, 48: 2214-2223. 10.1002/art.11097.CrossRefPubMed
20.
Selvaag AM, Flato B, Lien G, Sorskaar D, Vinje O, Forre O: Measuring health status in early juvenile idiopathic arthritis: determinants and responsiveness of the child health questionnaire. J Rheumatol. 2003, 30: 1602-1610.PubMed
21.
Tanner JM: Growth at adolescence. 1962, Blackwell scientific publications Oxford, 28-39. Second
22.
Waaler PE: Anthropometric studies in Norwegian children. Acta Paediatr Scand Suppl. 1983, 308: 1-41.PubMed
23.
Greulich WS, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist. 1959, Stanford: Stanford University Press
24.
Dale K, Paus AC, Laires K: A radiographic classification system in juvenile rheumatoid arthritis applied to the knee. Eur Radiol. 1994, 4: 27-32. 10.1007/BF00177383.CrossRef
25.
Selvaag AM, Flato B, Dale K, Lien G, Vinje O, Smerdel-Ramoya A, Forre O: Radiographic and clinical outcome in early juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3-year prospective study. J Rheumatol. 2006, 33: 1382-1391.PubMed
26.
Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P: Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. Eur J Endocrinol. 2001, 145: 685-690. 10.1530/eje.0.1450685.CrossRefPubMed
27.
Wu TL, Tsao KC, Chang CP, Li CN, Sun CF, Wu JT: Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range. Clin Chim Acta. 2002, 322: 163-168. 10.1016/S0009-8981(02)00172-9.CrossRefPubMed
28.
McDonagh JE: Osteoporosis in juvenile idiopathic arthritis. Curr Opin Rheumatol. 2001, 13: 399-404. 10.1097/00002281-200109000-00010.CrossRefPubMed
29.
Rabinovich CE: Bone mineral status in juvenile rheumatoid arthritis. [Review] [31 refs]. J Rheumatol. 2000, 27: 34-37.
30.
Szulc P, Seeman E, Delmas PD: Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int. 2000, 11: 281-294. 10.1007/s001980070116.CrossRefPubMed
31.
Lien G: Bone mass and bone turnover in patients with juvenile idiopathic arthritis. Early changes and long-term outcome. PhD thesis. 2005, Faculty of Medicine, University of Oslo
32.
Bishop N, Braillon P, Burnham J, Cimaz R, Davies J, Fewtrell M, Hogler W, Kennedy K, Mäkitie O, Mughal Z, Shaw N, Vogiatzi M, Ward K, Bianchi ML: Dual-energy X-ray aborptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD Pediatric Official Positions. J Clin Densitom. 2008, 11: 29-42. 10.1016/j.jocd.2007.12.004.CrossRefPubMed
33.
Altman DG: Relation between several variables. Practical statistics for medical research. Edited by: Altman DG. 1997, London: Chapman & Hall, 325-361.
34.
Prentice A, Parsons TJ, Cole TJ: Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr. 1994, 60: 837-842.PubMed
35.
Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K: RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum. 2007, 56: 977-983. 10.1002/art.22433.CrossRefPubMed
36.
Aukrust P, Lien E, Kristoffersen AK, Muller F, Haug CJ, Espevik T, Froland SS: Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency--possible immunologic and clinical consequences. Blood. 1996, 87: 674-681.PubMed
37.
Summers GD, Deighton CM, Rennie MJ, Booth AH: Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford). 2008, 47: 1124-1131. 10.1093/rheumatology/ken146.CrossRef
38.
Rall LC, Roubenoff R: Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford). 2004, 43: 1219-1223. 10.1093/rheumatology/keh321.CrossRef
39.
Schett G, Stach C, Zwerina J, Voll R, Manger B: How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008, 58: 2936-2948. 10.1002/art.23951.CrossRefPubMed
40.
Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB: Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum. 2004, 50: 3831-3843. 10.1002/art.20637.CrossRefPubMed
41.
Haynes D, Crotti T, Weedon H, Slavotinek J, Au V, Coleman M, Roberts-Thomson PJ, Ahern M, Smith MD: Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum. 2008, 59: 911-920. 10.1002/art.23818.CrossRefPubMed
42.
Kirwan JR, Bijlsma JW, Boers M, Shea BJ: Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007, CD006356-
43.
Selvaag AM, Lien G, Sorskaar D, Vinje O, Forre O, Flato B: Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study. J Rheumatol. 2005, 32: 1122-1130.PubMed
44.
Berntson L, Andersson GB, Fasth A, Herlin T, Kristinsson J, Lahdenne P: Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol. 2003, 30: 2275-2282.PubMed
45.
Damasio MB, Malattia C, Martini A, Toma P: Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatr Radiol. 2010, 40: 985-998. 10.1007/s00247-010-1612-z.CrossRefPubMed
46.
Spannow AH, Stenboeg E, Pfeiffer-Jensen M, Fiirgaard B, Haislund M, Ostergaard M, Andersen NT, Herlin T: Ultrasound and MRI Measurements of Joint Cartilage in Healthy Children: a Validation Study. Ultraschall Med. 2010
Metadata
Title
Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study
Authors
Gunhild Lien
Thor Ueland
Kristin Godang
Anne M Selvaag
Øystein T Førre
Berit Flatø
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2010
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/1546-0096-8-30

Other articles of this Issue 1/2010

Pediatric Rheumatology 1/2010 Go to the issue

Research

Sonographic evaluation of pediatric localized scleroderma: preliminary disease assessment measures

Case Report

Bullous lesions as a manifestation of systemic lupus erythematosus in two Mexican teenagers

Review

Review for the generalist: The antinuclear antibody test in children - When to use it and what to do with a positive titer

Research

Summary of worldwide pediatric malignancies reported after exposure to etanercept

Research

Comparing different revisions of the Childhood Health Assessment Questionnaire to reduce the ceiling effect and improve score distribution: Data from a multi-center European cohort study of children with JIA

Research

Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever